Pfizer Inc. $PFE Shares Purchased by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 85.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 45,251 shares of the biopharmaceutical company’s stock after acquiring an additional 20,858 shares during the period. Elevated Capital Advisors LLC’s holdings in Pfizer were worth $1,271,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PFE. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $28,000. HFM Investment Advisors LLC lifted its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. boosted its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited as AstraZeneca’s failed Phase 3 trial in a rare heart disease pushed investors toward rival drugmakers, including PFE. Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
• Positive Sentiment: Pfizer’s oncology franchise got some attention after reports suggesting recent FDA action on IBRANCE could improve the investment case for the company’s cancer portfolio. Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
• Positive Sentiment: Pfizer also highlighted ongoing pipeline work, including a Phase 1 bioavailability study and its MUST multiple myeloma study, reinforcing the company’s longer-term R&D pipeline narrative. Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study Pfizer’s MUST Study Offers Fresh Insight Into Tough‑to‑Treat Multiple Myeloma
• Neutral Sentiment: J.P. Morgan lowered its price target on Pfizer and kept a Neutral rating, which signals continued caution even though the firm still sees some upside from current levels. Pfizer (PFE) Receives a Hold from J.P. Morgan
• Neutral Sentiment: Additional headlines around Pfizer’s dividend appeal, valuation, and analyst commentary are likely reinforcing investor debate, but they do not point to a major fundamental shift by themselves. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Jim Cramer declined to recommend Pfizer despite its high dividend yield, reflecting ongoing skepticism about the stock’s near-term appeal. ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

Pfizer Stock Performance

Pfizer stock opened at $24.22 on Friday. The firm has a 50 day simple moving average of $25.41 and a 200-day simple moving average of $26.20. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a market cap of $138.02 billion, a price-to-earnings ratio of 18.49 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. During the same quarter last year, the firm earned $0.92 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and decreased their target price for the stock from $32.00 to $28.00 in a research note on Monday. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.56.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.